EQT

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Founded in 2005, Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to consumers across over 20 markets. The company's extensive library includes books in multiple languages, catering to diverse reading preferences.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Founded in 2005, Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to consumers across over 20 markets. The company's extensive library includes books in multiple languages, catering to diverse reading preferences.

Mollie is a technology-driven payments platform that enables merchants to integrate online payments quickly through a single, developer-friendly API. It processes payments for more than 50,000 clients and supports a broad range of local and global methods, including Mastercard, Visa, Amex, PayPal, iDEAL, Bancontact, SEPA Direct Debit, Giropay, SOFORT Banking, and other options. The platform emphasizes simplicity and reliability, offering features such as single-click payments, fraud monitoring, multicurrency processing, daily settlement management, and real-time accounting to streamline checkout, reduce costs, and manage funds on one platform. Mollie focuses on continuous innovation and ease of integration and is based in Amsterdam, the Netherlands.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

iSTAR Medical specializes in developing ophthalmic implants made from biomaterials. Its flagship product is the STARflo glaucoma implant, a non-degradable, precision-pore device designed to reduce intraocular pressure in open angle glaucoma patients by enhancing natural fluid outflow. The company's products are sold through distributors worldwide and it operates from its eco-friendly R&D and manufacturing facility near Namur, Belgium.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Veritas Petroleum Services provides testing, inspection and advisory solutions for the maritime sector, supported by five laboratories worldwide. It delivers fuel quality testing, bunker quantity surveys, oil condition monitoring and transformer oil testing, along with additional testing services and decarbonisation support. Through these offerings, the company helps clients optimize fuel management, reduce fuel costs, improve operational efficiency and ensure compliance with marine fuel regulatory requirements.

Azelis is a global distributor of specialty chemicals and food ingredients, offering a broad portfolio and value-added services to business customers. The company combines extensive local knowledge with an international network to support formulation, application development, and technical problem-solving, delivering tailored solutions. It serves multiple regions, including Europe, the Middle East and Africa, the Americas, and Asia-Pacific, and provides digital tools and online portals that help buyers access information on suppliers, products, and services.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband connectivity for over 350,000 households and businesses. The company has expanded its operations in recent years by rolling out fiber networks to underserved municipalities and remote areas. As a regional internet service provider, Caiway offers a comprehensive suite of services, including cable television, broadband internet, and telephony, utilizing advanced cable and fiber infrastructure. Key regions within its operational footprint include Westland, Schiedam, and Almelo, where it aims to deliver reliable networking solutions to enhance connectivity for its customers.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

TransIP Group B.V., established in 2003 and headquartered in Leiden, Netherlands, specializes in providing web hosting and related services. It caters primarily to tech-savvy customers and IT professionals, offering a range of products including virtual private servers, domain name registration, and web hosting. The company's notable services comprise BladeVPS PureSSD Pro, a self-managed tool with web control panels and operating systems, STACK for online file storage, syncing, and sharing, and SSL certificates for website encryption. Additionally, TransIP provides services like forwarding, big storage, and private network solutions. As of 2019, TransIP operates as a subsidiary of Combell nv.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of a new generation of biological drugs, utilizing a versatile and proprietary technology platform. This platform focuses on a delivery system that employs living non-pathogenic microorganisms for the oral administration of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, positioning itself at the forefront of innovative therapeutic solutions.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Scandic Hotels Group operates over 200 hotels across 120 destinations in seven countries, primarily in the Nordics. The company generates majority of its revenue from business travel and conferences.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of a new generation of biological drugs, utilizing a versatile and proprietary technology platform. This platform focuses on a delivery system that employs living non-pathogenic microorganisms for the oral administration of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, positioning itself at the forefront of innovative therapeutic solutions.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. Founded in 2006 and headquartered in Turnhout, Belgium, Movetis focuses on conditions such as severe chronic constipation, ascites, pediatric reflux, and complex GI motility disorders like refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is specifically developed for the symptomatic treatment of chronic constipation in women, with ongoing research to extend its use to males, children, and conditions like opioid-induced constipation and postoperative ileus. Movetis is also advancing other candidates in its pipeline, including M0002, currently in Phase II trials for ascites, and M0003, which is entering Phase II development for treating heartburn and pediatric reflux in patients resistant to proton pump inhibitors. Additionally, the company has prioritized compounds from its preclinical portfolio and maintains partnerships with several academic institutions in Belgium and the Netherlands to enhance its research capabilities.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Haanpaa Group is a logistics provider specializing in the distribution of liquid chemical products across Europe. Founded in 1949 by Jussi Haanpaa and headquartered in Vantaa, Finland, the company offers a comprehensive range of services, including storage, maintenance, transportation, and delivery of chemical products in several European cities. Haanpaa is also involved in sampling, monitoring, packaging, and tank inspection, catering to industries such as specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, and agricultural commodities. The company has expanded its operations with branches in Finland, Sweden, Norway, Estonia, Russia, and the Netherlands. Since July 2016, Haanpaa operates as a subsidiary of Groupe Samat SA.